| Trial ID # | NCT05489211 |
| Phase | II |
| Drug Class | Antibody Drug Conjugates: TROP2 |
| Drug Name | Datopotamab deruxtecan |
| Alternate Drug Names | Dato-DXd, Anti-TROP2/DXd antibody-drug conjugate DS-1062a |
| Drugs in Trial | Bevacizumab, Carboplatin, Datopotamab deruxtecan, Saruparib |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 26, median 2 prior therapies (1-2) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, evaluated per RECIST |
| Efficacy | ORR: 34.6% (9PR) |
| Clinically Significant Adverse Events | Serious AE: overall (28.6%) |
| Conclusion | Datopotamab deruxtecan (Dato-DXd) monotherapy demonstrates encouraging efficacy and a manageable safety profile in patients with platinum resistant or refractory ovarian cancer |
| Reference | Oaknin A et al. Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study. Ann Oncol (2024) 35 (2) abstract 714MO |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.